Skip to main content
SpringerLink
Log in

Antipsychotic Medication-Induced Dysphoria: Its Meaning, Association with Typical vs. Atypical Medications and Impact on Adherence

  • Original Paper
  • Published:
Psychiatric Quarterly Aims and scope Submit manuscript

Abstract

Antipsychotic medication-induced dysphoria is a relatively under-recognized and understudied effect of antipsychotic medication. Although the term is encountered in clinical practice and in the literature, there is no consensus regarding its exact meaning. This article is a narrative review of the literature on antipsychotic medication and dysphoria based on a pubmed database search. We found that antipsychotic medication-induced dysphoria is a term used to describe a negative and unpleasant affective state which seems to be more often associated with high potency first-generation antipsychotics and could potentially lead to medication non-adherence. Though it is plausible to expect antipsychotic medication-induced dysphoria to be related to extrapyramidal symptoms, most especially akathisia, the nature of the association remains unspecified. Furthermore, there is some evidence that dopamine blockade maybe involved in the pathogenesis of antipsychotic medication-induced dysphoria. However, the limited methods of the currently available studies make it impossible to conclusively address the question of which class of antipsychotic (first- or second-generation) has a higher prevalence and severity of the syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. King C, Voruganti LN: What’s in a name? The evolution of the nomenclature of antipsychotic drugs. Journal of Psychiatry and Neuroscience 27:168–175, 2002.

    PubMed Central  PubMed  Google Scholar 

  2. Harrison PJ: The neuropathological effects of antipsychotic drugs. Schizophrenia Research 40:87–99, 1999.

    Article  CAS  PubMed  Google Scholar 

  3. Leucht S, Pitschel-Walz G, Abraham D, Kissling W: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research 35:51–68, 1999.

    Article  CAS  PubMed  Google Scholar 

  4. King DJ, Burke M, Lucas RA: Antipsychotic drug-induced dysphoria. The British Journal of Psychiatry 167:480–482, 1995.

    Article  CAS  PubMed  Google Scholar 

  5. Lynch G, Green JF, King DJ: Antipsychotic drug-induced dysphoria. The British Journal of Psychiatry 169:524, 1996.

    Article  CAS  PubMed  Google Scholar 

  6. Noordsy DL, Drake RE, Teague GB, Osher FC, Hurlbut SC, Beaudett MS, et al.: Subjective experiences related to alcohol use among schizophrenics. The Journal of nervous and mental disease 179:410–414, 1991.

    Article  CAS  PubMed  Google Scholar 

  7. Mueser KT, Drake RE, Wallach MA: Dual diagnosis: a review of etiological theories. Addictive Behaviors 23:717–734, 1998.

    Article  CAS  PubMed  Google Scholar 

  8. Voruganti LN, Heslegrave RJ, Awad AG: Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse. The Journal of Nervous and Mental Disease 185:463–465, 1997.

    Article  CAS  PubMed  Google Scholar 

  9. Awad AG, Voruganti LN: Quality of life and new antipsychotics in schizophrenia. Are patients better off? International Journal of Social Psychiatry 45:268–275, 1999.

    Article  CAS  PubMed  Google Scholar 

  10. Singh MM, Smith JM: Kinetics and dynamics of response to haloperidol in acute schizophrenia–A longitudinal study of the therapeutic process. Comprehensive Psychiatry 14:393–414, 1973.

    Article  CAS  PubMed  Google Scholar 

  11. Caine ED, Polinsky RJ: Haloperidol-induced dysphoria in patients with Tourette syndrome. The American journal of psychiatry 136:1576, 1979.

    Article  Google Scholar 

  12. Bruun RD: Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette’s disorder. The American Journal of Psychiatry 145:621–624, 1988.

    Article  CAS  PubMed  Google Scholar 

  13. Weiden PJ, John Mann J, Dixon L, Haas G, Dechillo N, Frances AJ: Is neuroleptic dysphoria a healthy response? Comprehensive Psychiatry 30:546–552, 1989.

    Article  CAS  PubMed  Google Scholar 

  14. Newcomer JW, Miller LS, Faustman WO, Wetzel MW, Vogler GP, Csernansky JG: Correlations between akathisia and residual psychopathology: a by-product of neuroleptic-induced dysphoria. The British Journal of Psychiatry 164:834–838, 1994.

    Article  CAS  PubMed  Google Scholar 

  15. Awad AG, Voruganti L: New antipsychotics, compliance, quality of life, and subjective tolerability–are patients better off? Canadian Journal of Psychiatry 49:297–302, 2004.

    PubMed  Google Scholar 

  16. Voruganti L, Slomka P, Zabel P, Costa G, So A, Mattar A, et al: Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging. Neuropsychopharmacology 25:642–650, 2001.

    Article  CAS  PubMed  Google Scholar 

  17. Voruganti L, Awad AG: Brain imaging research on subjective responses to psychotropic drugs. Acta Psychiatrica Scandinavica 111:22–28, 2005.

    Article  Google Scholar 

  18. Voruganti L, Awad AG: Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berl) 171:121–132, 2004.

    Article  CAS  Google Scholar 

  19. Caine ED, Polinsky RJ: Haloperidol-induced dysphoria in patients with Tourette syndrome. The American Journal of Psychiatry 136:1216–1217, 1979.

    Article  CAS  PubMed  Google Scholar 

  20. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A: Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophrenia Research 43:135–145, 2000.

    Article  CAS  PubMed  Google Scholar 

  21. Voruganti L, Cortese L, Owyeumi L, Kotteda V, Cernovsky Z, Zirul S, et al.: Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophrenia Research 57:201–208, 2002.

    Article  CAS  PubMed  Google Scholar 

  22. Cook PE, Goldberg JO, and Van Lieshout RJ: Benefits of switching from typical to atypical antipsychotic medications: a longitudinal study in a community-based setting. Canadian Journal of Psychiatry 47:870–874, 2002.

    PubMed  Google Scholar 

  23. Naber D, Karow A, Lambert M: Subjective well-being under the neuroleptic treatment and its relevance for compliance. Acta Psychiatrica Scandinavica. Supplementum 111:29–34, 2005.

    Article  Google Scholar 

  24. Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, et al.: Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophrenia Research 50:79–88, 2001.

    Article  CAS  PubMed  Google Scholar 

  25. Harvey PD, Rabinowitz J, Eerdeken S, Davidson M: Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. The American Journal of Psychiatry 162:1888–1895, 2005.

    Article  PubMed  Google Scholar 

  26. Marder SR: Lessons from each drug trial. The American Journal of Psychiatry 164:375–376, 2007.

    Article  PubMed  Google Scholar 

  27. Naber D. Subjective effects of antipsychotic treatment. Acta Psychiatrica Scandinavica 111:81–83, 2005.

    Article  PubMed  Google Scholar 

  28. Opjordsmoen S, Melle I, Friis S, Haahr U, Johannessen JO, Larsen TK et al.: Stability of medication in early psychosis: a comparison between second-generation and low-dose first-generation antipsychotics. Early Intervention in Psychiatry 3:58–65, 2009.

    Article  PubMed  Google Scholar 

  29. Marder SR, Glynn SM, Wirshing WC, Wirshing DA, Ross D, Widmark C et al.: Maintenance treatment of schizophrenia with risperidone or haloperidol: 2 year outcomes. American Journal of Psychiatry 160:1405–1412, 2003.

    Article  PubMed  Google Scholar 

  30. Awad A, Hogan T: Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatrica Scandinavica 89:27–32, 1994.

    Article  Google Scholar 

  31. Van Putten T, May PR, Marder SR, Wittmann LA: Subjective response to antipsychotic drugs. Archives of General Psychiatry 38:187–190, 1981.

    Article  PubMed  Google Scholar 

  32. Van Putten T, May R: Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point. Archives of General Psychiatry 35:477–480, 1978.

    Article  PubMed  Google Scholar 

  33. Hogan T, Awad A: Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychological Medicine 22:347–352, 1992.

    Article  CAS  PubMed  Google Scholar 

  34. Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J: Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 6:8, 2006.

    Article  PubMed Central  PubMed  Google Scholar 

  35. Koob GF, Le Moal M: Drug abuse: hedonic homeostatic dysregulation. Science 278:52–58, 1997.

    Article  CAS  PubMed  Google Scholar 

  36. Fibiger HC: Neurobiology of depression: focus on dopamine. Advances in Biochemical Psychopharmacology 49:1–17, 1995.

    CAS  PubMed  Google Scholar 

  37. Self DW, Nestler EJ: Molecular mechanisms of drug reinforcement and addiction. Annual Review of Neuroscience 18:463–495, 1995.

    Article  CAS  PubMed  Google Scholar 

  38. Wise RA: Addictive drugs and brain stimulation reward. Annual Review of Neuroscience 19:319–340, 1996.

    Article  CAS  PubMed  Google Scholar 

  39. Voruganti L, Slomka P, Zabel P, Costa G, So A, Mattar A, et al.: Subjective effects of AMPT induced dopamine depletion in schizophrenia; the correlation between D2 binding ratio and dysphoric responses. Neuropsychopharmacology 25:642–650, 2001.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Texas Harris County Psychiatric Center, 2800 South MacGregor Way, Houston, TX, 77021, USA

    Hanjing Emily Wu & Olaoluwa O. Okusaga

  2. Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston, Houston, TX, USA

    Hanjing Emily Wu & Olaoluwa O. Okusaga

Authors
  1. Hanjing Emily Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olaoluwa O. Okusaga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Olaoluwa O. Okusaga.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, H.E., Okusaga, O.O. Antipsychotic Medication-Induced Dysphoria: Its Meaning, Association with Typical vs. Atypical Medications and Impact on Adherence. Psychiatr Q 86, 199–205 (2015). https://doi.org/10.1007/s11126-014-9319-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11126-014-9319-1

Keywords

Search

Navigation